Dr. Tolba on Targeting NRG1 Fusions in NSCLC

Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non-small cell lung cancer.

Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non—small cell lung cancer (NSCLC).

Recently presented during the 2019 World Conference on Lung Cancer, Tolba’s research shows that afatinib (Gilotrif) has activity in NRG1-fusion positive NSCLC. This adds to other research, however, a study with a larger cohort is suggested for the future.

<<< 2019 World Conference on Lung Cancer

Related Content:

IASLC World Conference on Lung CancerOncLive TV
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer
Dr Wander on Limitations of First- and Later-Line Therapies in HR+ Breast Cancer